GSK is set to buy Rapt Therapeutics in a $2.2 billion deal. AstraZeneca agreed to a $630 million pact to secure remaining rights to armored CAR-T from AbelZeta. Bristol Myers Squibb signed a deal with ...

While Eli Lilly LLY is a market leader in the GLP-1 segment, thanks to its tirzepatide medicines Mounjaro (for diabetes) and ...

British finance minister Rachel Reeves will accompany Prime Minister Keir Starmer on his trip to China next week, ...

(Alliance News) - HSBC Holdings Chair Brendan Nelson is among senior business figures set to travel to China with UK Prime Minister Keir Starmer next week, as the government seeks to reset relations ...

Daiichi Sankyo Co Ltd and AstraZeneca PLC on Thursday said Chinese regulators have approved their jointly developed drug Enhertu to treat gastric cancer. Enhertu is now cleared as a second-line ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...

Despite guideline recommendations and improved access to care, individuals with hypertension are unlikely to measure their blood pressure at home as often as recommended, according to data from ...

While a majority of the therapies currently in development are life-long treatments, Genespire is taking a different approach ...

The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape ...

Astrazeneca plc is paying up to $630 million to acquire China rights to Abelzeta's Pharma Inc.’s C-CAR031 (AZD5851), an autologous glypican 3-targeting CAR T, securing global rights to develop, ...

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

Major global pharmaceutical companies are significantly boosting their U.S. manufacturing capacities in response to potential ...